en · de · es · fr · pt
selank-notes.peptides6088.com › Blog › Mechanism And Evidence Base — Quick Reference

Mechanism And Evidence Base — Quick Reference

By Editorial Desk · published 2026-04-04 · last reviewed 2026-05-06 · Blog

Regulatory peptide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.

Updated 2026-05-06. Numbers and descriptions here follow the published literature rather than marketing material.

Mechanism and Evidence Base

Clinical evidence comes mainly from small studies conducted in Russia, several of which were open-label or lacked robust blinding. Reported outcomes include lower anxiety scores, changes in attention measures, and effects on asthenic states following illness. Sample sizes are typically in the tens of participants, and independent replication outside the region is scarce. Reviews published in English generally note the limited methodological quality of the underlying trials. Whether the compound produces clinically meaningful effects under rigorous conditions remains unresolved.

Proposed mechanisms center on modulation of the GABA system, but no single molecular target has been confirmed. Rodent studies report changes in GABA-A receptor expression and in the turnover of serotonin, dopamine, and norepinephrine in several brain regions. Increases in brain-derived neurotrophic factor and its receptor have also been described after repeated administration. These findings come largely from animal models, and the degree to which they describe human neurochemistry remains an open question. The mechanism is best characterized as multi-system and not fully resolved.

Proposed Mechanisms and Research Endpoints

Laboratory work relies on standard behavioral paradigms. Rodents are tested in the elevated plus maze, open field, and passive avoidance tasks, with outcomes compared against diazepam or vehicle controls. Intranasal dosing is used most often because it bypasses first-pass metabolism, though intraperitoneal and intravenous routes also appear in published protocols. Biochemical endpoints include tissue BDNF concentrations, cytokine levels, and monoamine metabolites. Human data are limited to small Russian trials reporting reduced anxiety scores; most were not prospectively registered, and few employed independent outcome assessment.

Measuring peptide exposure inside the brain is technically difficult. Selank is degraded rapidly in plasma, and assays must separate intact peptide from fragments, which favors targeted mass spectrometry over immunoassays alone. Reported half-lives are short, on the order of minutes, so effects observed hours later are attributed to downstream signaling rather than to the parent compound. Blood-brain barrier permeability is debated and rarely quantified directly. Gaps include absent dose-response characterization, inconsistent reporting of purity, and almost no pharmacokinetic data from human participants.

Selank is studied chiefly as an animal-model anxiolytic with proposed secondary effects on memory and immune signaling. Reported mechanisms include modulation of the GABA-A receptor complex, inhibition of enkephalin-degrading enzymes, and shifts in monoamine turnover within limbic structures. Some experiments describe increased expression of brain-derived neurotrophic factor in the hippocampus after repeated dosing. No single molecular target has been confirmed, and the peptide does not bind any receptor with the selectivity typical of a conventional small-molecule drug. Mechanism therefore remains a set of hypotheses rather than an established pathway.

Selank at a glance

PropertyValueNotes
Route studiedIntranasalPredominant route in published reports
Circulation stabilityShort, minutes scalePeptidases cleave it; the tail slows the process
Analytical methodRP-HPLC with mass spectrometryUsed for identity and purity assessment
Reported outcome domainsAnxiety and cognitive measuresDerived from small, mostly regional trials
Regulatory statusMarketed in RussiaAvailability outside that market is limited

Selank Background And Chemical Identity

Selank is a synthetic heptapeptide developed in Russia during the 1990s. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences designed it as a stabilized analog of tuftsin, a naturally occurring immunomodulatory tetrapeptide. The compound has been studied primarily for its reported anxiolytic and nootropic effects. It remains largely unknown in Western pharmacology and is not approved as a medicine by major regulators such as the FDA or the EMA.

The primary structure of Selank is Thr-Lys-Pro-Arg-Pro-Gly-Pro, corresponding to the molecular formula C33H57N11O9 and a monoisotopic mass of roughly 751.9 daltons. The N-terminal threonine and the arginine residue in the fourth position are shared with tuftsin, which carries the sequence Thr-Lys-Pro-Arg. The three additional residues at the C-terminus, Pro-Gly-Pro, extend the chain and are associated with greater resistance to enzymatic degradation. This extension also separates Selank from the shorter parent peptide.

Related pages on this site

Mechanism and Evidence Status

Proposed mechanisms centre on the GABAergic system. Animal and tissue studies report changes in GABA-A receptor expression and reduced activity of GABA transaminase, the enzyme that degrades GABA. Effects on monoamine turnover, including serotonin and dopamine pathways, are also described, and a separate line of work links the peptide to increased expression of brain-derived neurotrophic factor in hippocampal tissue. Most of these findings come from rodent models and cell preparations. How the individual observations combine into a single coherent mode of action is not settled.

Pharmacokinetic data are sparse and largely derived from animal work. After intranasal administration the peptide appears in plasma within minutes, and reported half-lives are short, on the order of minutes to tens of minutes. Degradation proceeds through ordinary proteolytic cleavage into constituent amino acids and smaller fragments. Direct evidence that intact Selank reaches brain tissue in meaningful amounts is limited, and the extent of blood-brain barrier penetration is debated. Some authors argue that fragments, not the parent peptide, carry much of the observed activity.

Published clinical work is concentrated in Russian-language journals and generally involves small samples without independent replication. Systematic reviews in English note the shortage of randomised, placebo-controlled trials and the difficulty of verifying methods from translated reports. Outcome measures vary between studies, which complicates pooling of results. Interest in the compound as a cognitive or anxiolytic agent therefore rests on a thinner evidence base than the volume of citations suggests. Replication in well-powered trials with preregistered endpoints would be needed before firm conclusions about efficacy can be drawn.

Origins and Proposed Mechanisms

Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences as a structural analogue of tuftsin, a naturally occurring tetrapeptide fragment of the immunoglobulin heavy chain. The added Pro-Gly-Pro tail was intended to slow enzymatic degradation and extend biological activity. In Russia it is registered as an anxiolytic nasal preparation, while regulators elsewhere have not approved it for clinical use.

Proposed mechanisms centre on modulation of the GABAergic system, with reports of altered expression of genes related to GABA-A receptor subunits and changed monoamine turnover. Some studies describe inhibition of enkephalinase, the enzyme that degrades endogenous enkephalins, which may prolong opioid peptide signalling. Effects on brain-derived neurotrophic factor and on cytokine expression have also been reported. These findings come largely from animal models and small human studies, and the precise primary target remains unresolved.

Further detail

=== Affinity chromatography === Affinity chromatography emerged in the 1950s as a rarely used method used to purify enzymes; it has since seen mainstream use and is the oldest among chemoproteomic approaches. Affinity chromatography is performed following one of two basic formats: ligand immobilization or target immobilization. Under the ligand immobilization format, a ligand of interest - often a drug lead - is immobilized within a chromatography column and acts as the stationary phase. A complex sample consisting of many proteins, such as a cell lysate, is passed through the column and the target of interest binds to the immobilized ligand while other sample components pass through the column unretained. Under the target immobilization format, a target of interest - often a disease-relevant protein - is immobilized within a chromatography column and acts as the stationary phase. Pooled compound libraries are then passed through the column in an application buffer, ligands are retained through binding interactions with the stationary phase, and other compounds pass through the column unretained. In both cases, retained analytes can be eluted from the column and identified using mass spectrometry. A table of elution strategies is provided below.

== Patents == U.S. patent 3,740,385 "N-Terminal Derivatives of Secretin", filed May 1970, issued June 1973 U.S. patent 4,199,512 "Compounds for alleviating hypertension", filed September 1978, issued April 1980 U.S. patent 4,154,935 "Halogen substituted mercaptoacylamino acids", filed September 1978, issued May 1978 U.S. patent 4,241,076 "Halogenated substituted mercaptoacylamino acids", filed May 1979, issued December 1980 U.S. patent 4,339,600 "Compounds for alleviating angiotensin related hypertension", filed February 1978, issued July 1982 U.S. patent 4,722,810 "Enkephalinase inhibitors", filed August 1986, issued February 1988

==== Distribution ==== The plasma protein binding of naltrexone is about 20% over a naltrexone concentration range of 0.1 to 500 μg/L. Its apparent volume of distribution at 100 mg orally is 16.1 L/kg after a single dose and 14.2 L/kg with repeated doses.

In one transient hot-wire study of monolithic silica aerogel, Cohen and Glicksman reported that the thermal conductivity decreased from 9.3 mW·m−1·K−1 (0.0093 W·m−1·K−1) at 1 atm to 3.2 mW·m−1·K−1 (0.0032 W·m−1·K−1) at 0.1 atm; the same aerogel in granular form had a thermal conductivity of 15.0 mW·m−1·K−1 at ambient gas pressure under modest compression. Its melting point is 1,473 K (1,200 °C; 2,192 °F). Until 2011, silica aerogel held 15 entries in Guinness World Records for material properties, including best insulator and lowest-density solid, though it was ousted from the latter title by the even lighter materials aerographite in 2012 and then aerographene in 2013.

Sources: en.wikipedia.org

Supporting material

=== Continued unrest === Over Christmas, the UDF called for supporters to observe a "Black Christmas" – a form of consumer boycott, among other things – to mourn the casualties. This led to a fortnight of "comparative calm", excepting a large-scale confrontation on Christmas Day in Sharpeville, where a large crowd had clashed with police after returning from a Black Christmas event at the graves of those killed. Violence broke out again in PWV after Boxing Day. Morale was boosted by the successes of the Vaal uprising – the government had been forced to make certain concessions, removing local councillors to safety and suspending the rent increases – and militant vigour was piqued both by the severe state response and by the presence of troops in the townships, taken by some as a "declaration of war". The increased presence of state security forces in the townships led to a proliferation of opportunistic violence against the forces' members, who – if present in small enough numbers, or if they had run out of ammunition – became a frequent target for stone-throwing. One account describes young militants developing elaborate strategies to obstruct the security services' work: digging trenches to prevent armoured vehicles from moving around, blocking roads with burning tyres and rocks, painting over house numbers and other identifiers to stop police from identifying activists' houses, and staking out "liberated areas" where police and other state representatives could not go.

Additionally, increasing levels of OGT for O-GlcNAcylation may have therapeutic effects for Alzheimer's disease patients. Brain glucose metabolism is impaired in Alzheimer's disease, and a study suggests that this leads to hyperphosphorylation of tau and degerenation of tau O-GlcNCAcylation. Replenishing tau O-GlcNacylation in the brain along with protein phosphatase could deter this process and improve brain glucose metabolism.

The country had a 2019 Forest Landscape Integrity Index mean score of 5.95/10, ranking it 90th globally out of 172 countries. Some 3,700 plant species have been identified in the country, from which to date 23 have been declared natural monuments, 74 extinct, 39 endangered, 171 vulnerable, and 1,253 rare. The fauna of Romania consists of 33,792 species of animals, 33,085 invertebrate and 707 vertebrate, with almost 400 unique species of mammals, birds, reptiles, and amphibians, including about 50% of Europe's (excluding Russia) brown bears and 20% of its wolves. Romania is often seen by most as having the shape resembling one of a goldfish.

Sources: en.wikipedia.org

Notes from published material

However, the reduction of seizure threshold could be attributed to tramadol's putative inhibition of GABAA receptors at high doses (significant inhibition at 100 μM). In addition, desmetramadol is a high-affinity ligand of the DOR, and activation of this receptor could be involved in tramadol's ability to provoke seizures in some individuals, as DOR agonists are well known for inducing seizures. Nausea and vomiting caused by tramadol are thought to be due to activation of the 5-HT3 receptor via increased serotonin levels. In accordance, the 5-HT3 receptor antagonist ondansetron can be used to treat tramadol-associated nausea and vomiting. Tramadol and desmetramadol themselves do not bind to the 5-HT3 receptor.

There is evidence that many types of slow-growing dinosaurs, including various theropods, sauropods, ankylosaurians, ornithopods, and ceratopsians, formed aggregations of immature individuals. One example is a site in Inner Mongolia that has yielded remains of over 20 Sinornithomimus, from one to seven years old. This assemblage is interpreted as a social group that was trapped in mud. The interpretation of dinosaurs as gregarious has also extended to depicting carnivorous theropods as pack hunters working together to bring down large prey. However, this lifestyle is uncommon among modern birds, crocodiles, and other reptiles (though it is not unknown as frequently assumed, and is also uncommon in mammals), and the taphonomic evidence suggesting cooperative hunting in such theropods as Deinonychus and Allosaurus can also be interpreted as the results of fatal disputes between feeding animals.

==== DP_PWR (pin 20) ==== Pin 20 on the DisplayPort connector, called DP_PWR, provides 3.3 V (±10%) DC power at up to 500 mA (minimum power delivery of 1.5 W). This power is available from all DisplayPort receptacles, on both source and display devices. DP_PWR is intended to provide power for adapters, amplified cables, and similar devices, so that a separate power cable is not necessary. Standard DisplayPort cable connections do not use the DP_PWR pin. Connecting the DP_PWR pins of two devices directly together through a cable can create a short circuit which can potentially damage devices, since the DP_PWR pins on two devices are unlikely to have exactly the same voltage (especially with a ±10% tolerance). For this reason, the DisplayPort 1.1 and later standards specify that passive DisplayPort-to-DisplayPort cables must leave pin 20 unconnected. However, in 2013 VESA announced that after investigating reports of malfunctioning DisplayPort devices, it had discovered that a large number of non-certified vendors were manufacturing their DisplayPort cables with the DP_PWR pin connected:

Sources: en.wikipedia.org

Frequently asked questions

What mechanisms are proposed for Selank?

Reports describe effects on GABA-A receptor expression, monoamine turnover, and neurotrophic factor levels. These are proposed mechanisms drawn mainly from animal models. No single molecular target has been established.

How is Selank typically given in studies?

Intranasal delivery is the route described in most published work. It is used because the peptide is degraded quickly once it reaches circulation. Direct evidence of brain penetration in humans is lacking.

How strong is the clinical evidence?

Most trials are small, regionally concentrated, and often lack rigorous blinding or placebo control. Independent replication is limited. Reviews in English generally rate the evidence as preliminary.

How is Selank administered in studies?

Intranasal administration predominates in both animal and human research because it avoids hepatic first-pass metabolism. Injectable and intraperitoneal routes appear in animal work mainly for comparison.

Network